KalVista Pharmaceuticals Announces Positive Interim Phase 3 Data for EKTERLY (sebetralstat) in Children with Hereditary Angioedema

KalVista Pharmaceuticals announced positive interim results from its KONFIDENT-KID trial evaluating EKTERLY (sebetralstat) for hereditary angioedema (HAE) attacks in children aged 2-11. The trial featured a proprietary oral disintegrating tablet formulation of sebetralstat, which was well-tolerated and achieved rapid symptom relief. Among 172 HAE attacks in 33 pediatric participants, the mean number of attacks treated per patient per month was 0.7, and median time to treatment was 25 minutes. The company plans to file a new drug application in the US in Q3 2026 with a launch anticipated in 2027.